What are the measles vaccines?
IMPORTANT NOTE: Corvelva invites you to get in-depth information by reading all the sections and links, as well as the manufacturer's product leaflets and technical data sheets, and to speak with one or more trusted professionals before deciding to vaccinate yourself or your child. This information is for informational purposes only and is not intended as medical advice.
There is no monovalent anti-measles vaccine on the market in Italy and the possible formulations are Trivalent (Measles, Rubella, Mumps) or Tetravalent (Measles, Rubella, Mumps, Varicella).
MMR vaccines (Measles, Rubella, Mumps)
MM-RVAXPRO - Merck Sharp & Dohme BV (click to open)
Measles, mumps and rubella vaccine (live) and is indicated for simultaneous vaccination against measles, mumps and rubella in individuals from 12 months of age
Dosage declared by the manufacturer
The vaccination cycle involves a single administration. A second dose can be given at least 4 weeks after the first dose. The second dose is indicated for subjects who have not responded to the first dose for any reason
Adverse events declared by the manufacturer
- Nasopharyngitis, upper respiratory tract infection or viral infection
- Aseptic meningitis, atypical measles, epididymitis, orchitis, otitis media, mumps, rhinitis, subacute sclerosing panencephalitis
- Local lymphadenopathy, thrombocytopenia
- Anaphylactoid reaction, anaphylaxis and related phenomena such as angioneurotic edema, facial edema and peripheral edema
- Cry
- Irritability
- Convulsions or fits without fever, ataxia, dizziness, encephalitis, encephalopathy, febrile convulsion (in children), Guillain-Barré syndrome, headache, measles encephalitis with inclusion bodies
- (MIBE: measles inclusion body encephalitis), ocular palsy, optic neuritis, paraesthesia, polyneuritis, polyneuropathy, retrobulbar neuritis, syncope
- Conjunctivitis, retinitis
- Sensorineural deafness
- Rhinorrhea
- Bronchial spasm, cough, lung inflammation, pneumonia, sore throat
- diarrhea or vomiting
- Nausea
- Morbilliform rash or other rash
- Urticaria
- Panniculitis, pruritus, purpura, skin induration, Stevens-Johnson syndrome
- Arthritis and/or arthralgia (usually transient and rarely chronic), myalgia
- Fever (38,5°C or higher), injection site erythema, injection site pain, and injection site swelling
- Ecchymosis at the injection site
- Injection site rash
- Burning and/or stinging of short duration at injection site, malaise, papillitis, peripheral oedema, swelling, tenderness, injection site blistering, injection site bruising and warmth
- Vasculitis
Composition declared by the manufacturer
- Edmonston Enders strain measles virus (live, attenuated) produced on chick embryonic cells
- Mumps virus strain Jeryl Lynn™ (Level B) (live, attenuated) produced on chicken embryonic cells
- Rubella virus2 strain Wistar RA 27/3 (live, attenuated) produced on human diploid lung fibroblasts WI-38
- Recombinant human albumin (rHA)
- Sorbitol (E 420)
- Sodium Phosphate (NaH2PO4/Na2HPO4)
- Potassium Phosphate (KH2PO4/K2HPO4)
- Sucrose
- Hydrolyzed gelatin
- Medium 199 with Hanks salts
- Eagle Minimum Mean (MEM)
- Sodium L-glutamate
- Neomycin
- Phenol red
- Sodium bicarbonate (NaHCO3)
- Hydrochloric acid (HCl) (for pH adjustment)
- Sodium hydroxide (NaOH) (for pH adjustment)
- Water for injections
MMRV vaccines (Measles, Rubella, Mumps, Varicella)
ProQuad - Merck Sharp & Dohme BV (click to open)
Measles, mumps, rubella and varicella vaccine (live). It is indicated for children from 12 months of age
Dosage declared by the manufacturer
Individuals 12 months of age and older are given two doses or a single dose of ProQuad followed by a second dose of a monovalent varicella vaccine to achieve optimal protection against chickenpox. At least one month should elapse between the first and second dose of any live attenuated viral vaccine
Adverse events declared by the manufacturer
- Ear infection, gastroenteritis, otitis media, pharyngitis, infection
- viral, viral rash
- Cellulitis, respiratory tract infection, skin infection, tonsillitis,
- chickenpox, viral conjunctivitis
- Aseptic meningitis, encephalitis, epididymitis, herpes zoster, infection, measles, orchitis, mumps
- Leukocytosis, lymphadenopathy
- Lymphadenitis, thrombocytopenia
- Hypersensitivity
- Anaphylactoid reaction, anaphylactic reaction, angioedema, face edema and peripheral edema
- Decreased appetite
- Dehydration
- Irritability
- Crying, sleep disturbances
- Apathy, addiction, restlessness
- Febrile seizure, somnolence
- Ataxia, seizure, headache, hyperkinesia, hypersomnia, lethargy, tremor
- Bell's palsy, cerebrovascular accident, dizziness, encephalopathy, Guillain-Barré syndrome, measles inclusion body encephalitis, ocular palsy, paraesthesia, polyneuropathy, subacute sclerosing panencephalitis, syncope, transverse myelitis
- Conjunctivitis, eye discharge, blepharitis, eye irritation, eye swelling, ocular hyperaemia, lacrimation increased, eye discomfort
- Eyelid edema, optic neuritis, retinitis, retrobulbar neuritis
- Ear pain
- Sensorineural deafness
- Redness, pallor
- Extravasation
- Cough, respiratory tract congestion, rhinorrhea
- Sinus pathology, sneezing, wheezing
- Bronchospasm, bronchitis, pneumonia, lung infection, rhinitis, sinusitis, oropharyngeal pain
- Diarrhea, vomiting
- Upper abdominal pain, nausea, stomatitis
- Abdominal pain, hematochezia
- Measles-like rash, rash, chicken pox-like rash
- Dermatitis (including contact and atopic dermatitis), rubella-like rash, urticaria, erythema
- Cold sweat, dermatitis exfoliative, drug eruption, Henoch-Schönlein purpura, rash papular, pruritus, skin discolouration, skin lesion, zosteriform rash
- Erythema multiforme, panniculitis, purpura, skin induration, Stevens-Johnson syndrome
- Arm pain, musculoskeletal stiffness
- Arthritis, arthralgia, musculoskeletal pain, myalgia, swelling
- Fever, rash, or injection site pain/tenderness/irritation
- Ecchymosis or swelling at the injection site, injection site rash
- Asthenia, fatigue, injection site haemorrhage, injection site induration, injection site mass, malaise
- Influenza-like illness, injection site peeling, injection site discolouration, injection site pruritus, injection site reaction, injection site scar, hyperthermia, pain
- Injection site discomfort (pain, oedema, urticaria, hematoma, induration, mass, vesicles), inflammation, papillitis
- Weight loss
- Bruise
- Impaired activities of daily living
Composition declared by the manufacturer
- Edmonston Enders strain measles virus (live, attenuated) produced on chick embryonic cells
- Mumps virus strain Jeryl Lynn™ (Level B) (live, attenuated) produced on chicken embryonic cells
- Rubella virus strain Wistar RA 27/3 (live, attenuated) produced on human diploid lung fibroblasts (WI-38)
- Varicella virus Oka/Merck strain (live, attenuated) produced on human diploid cells (MRC-5)
- Recombinant human albumin (rHA)
- Sucrose
- Hydrolyzed gelatin
- Sodium chloride
- Sorbitol (E 420)
- Sodium glutamate
- Sodium phosphate
- Sodium bicarbonate
- Potassium phosphate
- Potassium chloride
- Medium 199 with Hanks salts
- Eagle Minimum Mean (MEM)
- Neomycin
- Phenol red
- Hydrochloric acid (to adjust pH)
- Sodium hydroxide (for pH adjustment)
- Urea
- Solvent Water for injections
Priorix Tetra - GlaxoSmithKline (click to open)
Measles, mumps, rubella and varicella vaccine (live).
Priorix Tetra is a vaccine used in children from 11 months up to and including 12 years of age to prevent diseases caused by the measles, mumps, rubella and chicken pox viruses
Dosage declared by the manufacturer
Individuals from 11 months of age should receive two doses of Priorix Tetra.
The interval between doses should preferably be between 6 weeks and 3 months. When the first dose is given at 11 months of age, the second dose should be given within 3 months. In no case should the interval between doses be less than 4 weeks.
Alternatively, individuals who have already received or will receive a single dose of another measles, mumps and rubella (MMR) vaccine and/or a single dose of another vaccine against chicken pox.
Adverse events declared by the manufacturer
NB Events were recorded up to 42 days after vaccination.
- Upper respiratory tract infection
- Rare otitis media
- Lymphadenopathy
- Anorexia
- Irritability
- Crying, nervousness, insomnia
- Febrile seizures
- Rhinitis
- Cough, bronchitis
- Swelling of the parotid glands, diarrhoea, vomiting
- Rash
- Injection site pain and redness, fever (rectal ≥38°C - ≤39,5°C; axillary/oral: ≥37,5°C - ≤39°C)
- Injection site swelling, fever (rectal >39,5°C; axillary/oral >39°C)
- Lethargy, malaise, fatigue
- Meningitis, herpes zoster, measles-like syndrome, mumps-like syndrome (including orchitis, epididymitis and mumps)
- Thrombocytopenia, thrombocytopenic purpura
- Allergic reactions (including anaphylactic and anaphylactoid reactions)
- Encephalitis, cerebellitis, cerebrovascular accident, Guillain Barré syndrome, transverse myelitis, peripheral neuritis, cerebellitis-like symptoms (including transient gait disturbance and transient ataxia)
- Vasculitis
- Erythema multiforme, varicella-like rash
- Arthralgia, arthritis
Composition declared by the manufacturer
- Measles virus Schwarz strain (live, attenuated) grown in chick embryo cell culture
- Mumps virus strain RIT 4385, derived from Jeryl Lynn strain (live, attenuated) grown in chick embryonic cell cultures
- Rubella virus strain Wistar RA 27/3 (live, attenuated) cultured in human diploid cells (MRC-5)
- Varicella virus OKA strain (live, attenuated) cultured in human diploid cells (MRC-5)
- Neomycin
- Amino acids (containing phenylalanine)
- Lactose anhydrous Mannitol (E421)
- Sorbitol (E420)
- Medium 199 (containing Phenylalanine, para-aminobenzoic acid, sodium, potassium)
- Water for injections
